Literature DB >> 19091352

Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.

Esther Tanja Kok1, Boris W Schouten, Arthur M Bohnen, Frans P M W Groeneveld, Siep Thomas, J L H Ruud Bosch.   

Abstract

PURPOSE: We explored risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in the open population.
MATERIALS AND METHODS: A longitudinal, population based study with a followup of 6.5 years was done in 1,688 men who were 50 to 78 years old. Data were collected on transrectal ultrasound of prostate volume, urinary flow rate, ultrasound estimated post-void residual urine volume, generic and disease specific quality of life, and symptom severity based on the International Prostate Symptom Score. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia were defined as an International Prostate Symptom Score of greater than 7 after a report of a score of less than 7 in the previous round. A multivariate Cox proportional hazard model was constructed to determine risk factors for clinical benign prostatic hyperplasia after correcting for patient age.
RESULTS: Total followup was 4,353 person-years. During followup 180 events of attaining an International Prostate Symptoms Score of greater than 7 occurred. Multivariate analysis showed that functional bladder capacity, post-void residual urine volume, treatment for cardiac diseases, education level, antidepressant use, calcium antagonist use, erectile function or dysfunction, prostate specific antigen and a family history of prostate cancer were determinants with a significant HR.
CONCLUSIONS: In addition to age, we established 9 significant determinants for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. However, not all risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia are accounted for since we can conclude that 1 of 3 men without these risk factors will still be diagnosed with lower urinary tract symptoms suggestive of benign prostatic hyperplasia between ages 50 and 80 years.

Entities:  

Mesh:

Year:  2008        PMID: 19091352     DOI: 10.1016/j.juro.2008.10.025

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

1.  Commonly used antihypertensives and lower urinary tract symptoms: results from the Boston Area Community Health (BACH) Survey.

Authors:  Susan A Hall; Gretchen R Chiu; David W Kaufman; Gary A Wittert; Carol L Link; John B McKinlay
Journal:  BJU Int       Date:  2011-09-27       Impact factor: 5.588

2.  Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.

Authors:  Joachim Troost; Shinji Tatami; Yasuhiro Tsuda; Michaela Mattheus; Ludwig Mehlburger; Martina Wein; Martin C Michel
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

3.  Sexual function outcome following photoselective vaporisation of the prostate.

Authors:  Tania A Hossack; Henry H Woo
Journal:  Int Urol Nephrol       Date:  2011-07-21       Impact factor: 2.370

Review 4.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

5.  Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older.

Authors:  Richard Berges; Matthias Oelke
Journal:  World J Urol       Date:  2011-01-08       Impact factor: 4.226

6.  A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms.

Authors:  Alison M Mondul; Edward Giovannucci; Elizabeth A Platz
Journal:  J Urol       Date:  2013-09-25       Impact factor: 7.450

7.  Clinical Implications of Residual Urine in Korean Benign Prostatic Hyperplasia (BPH) Patients: A Prognostic Factor for BPH-Related Clinical Events.

Authors:  Young Hwii Ko; Ji Yun Chae; Seung Min Jeong; Jae Il Kang; Hong Jae Ahn; Hyung Woo Kim; Sung Gu Kang; Hoon Ah Jang; Jun Cheon; Je Jong Kim; Jeong Gu Lee
Journal:  Int Neurourol J       Date:  2010-12-31       Impact factor: 2.835

8.  The Distribution of Post-Void Residual Volumes in People Seeking Care in the Symptoms of Lower Urinary Tract Dysfunction Network Observational Cohort Study With Comparison to Asymptomatic Populations.

Authors:  Andrew C Peterson; Abigail R Smith; Matthew O Fraser; Claire C Yang; John O L DeLancey; Brenda W Gillespie; John L Gore; Pooja Talaty; Victor P Andreev; Karl J Kreder; Margaret G Mueller; H Henry Lai; Bradley A Erickson; Ziya Kirkali
Journal:  Urology       Date:  2019-04-21       Impact factor: 2.649

Review 9.  Diabetes and benign prostatic hyperplasia: emerging clinical connections.

Authors:  Aruna V Sarma; J Kellogg Parsons
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

10.  Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH).

Authors:  Michael A Kozminski; John T Wei; Jason Nelson; David M Kent
Journal:  BJU Int       Date:  2014-08-13       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.